KR20220140808A - 타우병증의 치료 방법 - Google Patents

타우병증의 치료 방법 Download PDF

Info

Publication number
KR20220140808A
KR20220140808A KR1020227031617A KR20227031617A KR20220140808A KR 20220140808 A KR20220140808 A KR 20220140808A KR 1020227031617 A KR1020227031617 A KR 1020227031617A KR 20227031617 A KR20227031617 A KR 20227031617A KR 20220140808 A KR20220140808 A KR 20220140808A
Authority
KR
South Korea
Prior art keywords
deuterated
optionally substituted
ester
acid
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227031617A
Other languages
English (en)
Korean (ko)
Inventor
미하일 세르기비치 셰피노브
Original Assignee
레트로토프 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 레트로토프 인코포레이티드 filed Critical 레트로토프 인코포레이티드
Publication of KR20220140808A publication Critical patent/KR20220140808A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227031617A 2020-02-14 2021-02-12 타우병증의 치료 방법 Pending KR20220140808A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062976958P 2020-02-14 2020-02-14
US62/976,958 2020-02-14
PCT/US2021/017981 WO2021163580A1 (en) 2020-02-14 2021-02-12 Methods for treating tauopathy

Publications (1)

Publication Number Publication Date
KR20220140808A true KR20220140808A (ko) 2022-10-18

Family

ID=77273602

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227031617A Pending KR20220140808A (ko) 2020-02-14 2021-02-12 타우병증의 치료 방법

Country Status (9)

Country Link
US (2) US20210251933A1 (enExample)
EP (1) EP4103169A4 (enExample)
JP (2) JP2023513901A (enExample)
KR (1) KR20220140808A (enExample)
CN (1) CN116507325A (enExample)
AU (1) AU2021220981A1 (enExample)
CA (1) CA3171330A1 (enExample)
IL (1) IL295512A (enExample)
WO (1) WO2021163580A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240064584A (ko) * 2021-02-05 2024-05-13 레트로토프 인코포레이티드 중수소화 아라키돈산을 사용한 신경퇴행성 질환의 치료에 대한 환자의 반응을 평가하는 방법
US11510889B2 (en) 2021-02-05 2022-11-29 Retrotope, Inc. Methods for inhibiting the progression of neurodegenerative diseases
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
US11491130B2 (en) 2021-02-05 2022-11-08 Retrotope, Inc. Methods of treating amyotrophic lateral sclerosis
US20230165824A1 (en) * 2021-09-03 2023-06-01 Biojiva Llc METHODS, SYSTEMS AND COMPOSITIONS FOR INHIBITION OF CELLULAR DYSFUNCTION AND CELL DEATH WITH DEUTERATED PUFAs
CN118201607A (zh) * 2021-09-03 2024-06-14 拜奥吉瓦有限责任公司 利用氘代pufa抑制细胞功能障碍和细胞死亡的方法、系统和组合物
CA3243042A1 (en) * 2021-12-21 2025-04-08 Biojiva Llc METHODS AND COMPOSITIONS INTENDED FOR THE TREATMENT OF INFLAMMATORY DISEASE
WO2023192406A2 (en) * 2022-03-30 2023-10-05 Retrotope, Inc. Prophylactic methods for treating als

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2493296T3 (en) 2009-10-30 2019-04-15 Retrotope Inc REMOVAL OF OXIDATIVE STRESS STATES WITH PUFA DERIVATIVES
US10058522B2 (en) * 2011-04-26 2018-08-28 Retrotope, Inc. Oxidative retinal diseases
US10154983B2 (en) * 2011-04-26 2018-12-18 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating PUFAs
WO2018094116A1 (en) * 2016-11-17 2018-05-24 Retrotope, Inc. Isotopically modified components and therapeutic uses thereof
EP3461479B1 (en) * 2017-09-27 2021-06-16 Julie Blivet Nutraceutical and pharmaceutical compositions, and uses thereof for preserving cognitive functions
EP3806841A1 (en) * 2018-06-15 2021-04-21 Flagship Pioneering Innovations V, Inc. Decreasing immune activity through modulation of postcellular signaling factors

Also Published As

Publication number Publication date
US20210251933A1 (en) 2021-08-19
JP2026035680A (ja) 2026-03-04
US20250177339A1 (en) 2025-06-05
JP2023513901A (ja) 2023-04-04
CN116507325A (zh) 2023-07-28
AU2021220981A1 (en) 2022-09-22
WO2021163580A1 (en) 2021-08-19
EP4103169A4 (en) 2024-03-13
IL295512A (en) 2022-10-01
CA3171330A1 (en) 2021-08-19
EP4103169A1 (en) 2022-12-21

Similar Documents

Publication Publication Date Title
US20250177339A1 (en) Methods for Treating Tauopathy
US12030863B2 (en) Prodrugs of urolithins and uses thereof
ES2812800T3 (es) Nuevos usos terapéuticos de derivados de la bencilidenguanidina para el tratamiento de proteopatías
US20250215026A1 (en) Deuterated Compounds, Compositions and Uses
AU2020305979B2 (en) Method for treating idiopathic pulmonary fibrosis
EP3542629A2 (en) Dithiol compounds, derivatives, and uses therefor
US12310940B2 (en) Cell-permeable succinate compounds
US12251373B2 (en) Compounds and methods of treating retinal degeneration
US20160136164A1 (en) Methods and Compositions for the Treatment of Cancer and Related Hyperproliferative Disorders
ES2683184T3 (es) Inhibidores de GLyT1 para su uso en el tratamiento de trastornos hemáticos
CN102802622A (zh) 用于治疗缺血和缺血再灌注损伤的组合物和方法
US11564924B2 (en) Pharmaceutical composition formed by combining pyridoxamine compound and thiamine compound
AU2024203890A1 (en) Deuterated oxophenylarsine compound and use thereof
ES2959243T3 (es) Nuevo tratamiento de enfermedades mitocondriales
WO2017168137A1 (en) Pyrimidobenzimidazoles for use in the treatment and prevention of neurodegenerative disorders
EP2522394B1 (en) Substituted phosphonates and their use decreasing amyloid aggregates
JP7598195B2 (ja) 肥満及び関連する障害の予防及び治療のための化合物
WO2018170410A1 (en) Derivatives of sulindac can protect normal cells against oxidative damage
Tan et al. Lithium co-crystals and an additional neuropsychiatric agent for treatment of neuropsychiatric disorders
RU2780450C2 (ru) Применение бензоата для лечения нарушений центральной нервной системы
JP2025533497A (ja) タウ凝集阻害剤としてのチアゾール誘導体
BR112016023086B1 (pt) Composto, composição, e, uso de um composto

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000